DNA单核苷酸钠注射液辅助治疗肝损害性肺结核的临床研究

Clinical study of deoxyribonucleotidum for adjuvant treatment of pulmonary tuberculosis with hepatic lesion

目的探讨DNA单核苷酸钠注射液在肺结核治疗中的作用和临床应用价值。方法将确诊肺结核并经过抗结核治疗后出现肝损害的初治肺结核患者80例随机分成两组:对照组给予常规保肝治疗;治疗组在常规治疗基础上,加用DNA单核苷酸钠注射液。比较两组患者治疗前后肝功能变化、体液免疫指标和细胞免疫指标变化。结果治疗后2周和4周时,治疗组丙氨酸转氨酶、门冬氨酸转氨酶、碱性磷酸酶明显低于对照组(P<0.05),治疗后4周时,治疗组血清总胆红素亦明显低于对照组(P<0.05);治疗组治疗后第4周外周血IgG、IgA、IgM水平和外周血T淋巴细胞(CD3+)、CD8+T淋巴细胞亚群的比例明显高于治疗前(P<0.05),对照组治疗前后免疫指标变化无显著性差异。结论DNA单核苷酸钠注射液可以改善抗结核药物引起的肝损害,并能增强肺结核患者免疫力。

Objective To evaluate of therapeutic efficacy of deoxyribouncleotidum on pulmonary tuberculosis. Methods Eighty patients with pulmonary tuberculosis sustaining hepatic lesion after treatment with antituberculosis drugs were randomized into therapeutic group and control group. Patients in the control group received regular treatment and those in the therapeutic group had additional deoxyribouncleotidum injection. Results ALT, AST, ALP and TBIL levels were significantly higher in the therapeutic group than in the control group 4 weeks after treatment. IgG, IgA, IgM levels, and CD3^＋ and CD8^＋ lymphocytes were significantly increased in the therapeutic group after treatment （P〈0.05）. Conclusion deoxyribouncleotidum can improve hepatic function and immunity in patients with pulmonary tuberculosis,